Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies
about
Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.
P2860
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dose-escalation study of fixed ...... in advanced solid malignancies
@en
Dose-escalation study of fixed ...... n advanced solid malignancies.
@nl
type
label
Dose-escalation study of fixed ...... in advanced solid malignancies
@en
Dose-escalation study of fixed ...... n advanced solid malignancies.
@nl
prefLabel
Dose-escalation study of fixed ...... in advanced solid malignancies
@en
Dose-escalation study of fixed ...... n advanced solid malignancies.
@nl
P2093
P2860
P1476
Dose-escalation study of fixed ...... in advanced solid malignancies
@en
P2093
Amye J Tevaarwerk
Anne M Traynor
Daniel L Mulkerin
Dona B Alberti
Howard H Bailey
James F Cleary
Jens C Eickhoff
Kyle D Holen
Michael S Huie
P2860
P2888
P356
10.1007/S00280-008-0844-1
P577
2008-10-08T00:00:00Z